Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What do new lytics add to t-PA?

F Van de Werf1

  • 1Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium.

American Heart Journal
|July 30, 1999
PubMed
Summary

New approaches to thrombolytic therapy, including single-bolus fibrinolysis and glycoprotein IIb/IIIa receptor antagonists, aim to improve reperfusion in acute coronary syndromes. These strategies show promise for earlier, more effective clot lysis without increased bleeding risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNA Profiling in Human and Murine Transplanted Hearts: Identification and Validation of Therapeutic Targets for Acute Cardiac and Renal Allograft Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Dabigatran versus warfarin in patients with mechanical heart valves: reply.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology.

Acute cardiac care·2011
Same author

Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve.

Quality & safety in health care·2010
Same author

[Implementation of reperfusion therapy in ST segment elevation myocardial infarction (STEMI). A policy statement from the Belgian Society of Cardiology and its working group of acute cardiology and interventional cardiology].

Revue medicale de Bruxelles·2010
Same author

[Implementation of reperfusion therapy in ST segment elevation myocardial infarction (STEMI). A policy statement from the Belgian Society of Cardiology and its working group of acute cardiology and interventional cardiology].

Revue medicale de Liege·2010

Area of Science:

  • Cardiology
  • Pharmacology
  • Emergency Medicine

Background:

  • Current thrombolytic therapy for ST-segment elevation acute coronary syndromes has limited efficacy, failing to achieve reperfusion in approximately 50% of patients.
  • Existing treatments often lack early, complete, and sustained reperfusion, necessitating improved therapeutic strategies.

Purpose of the Study:

  • To explore advancements in thrombolytic therapy for acute coronary syndromes.
  • To evaluate novel fibrinolytics and antithrombotic agents for enhanced clot lysis and reperfusion.
  • To assess the potential of single-bolus administration and glycoprotein IIb/IIIa receptor antagonists in improving treatment outcomes.

Main Methods:

  • Investigated the development of novel fibrinolytics with improved fibrin specificity and reduced plasma clearance.
  • Examined the coadministration of new antithrombotic agents, specifically glycoprotein IIb/IIIa receptor antagonists.
  • Assessed the efficacy and safety of single-bolus fibrinolytic therapy compared to current infusion methods.

Main Results:

  • Single-bolus fibrinolytic therapy is emerging as a likely replacement for current infusions, enabling earlier prehospital treatment.
  • Concomitant intravenous administration of glycoprotein IIb/IIIa receptor antagonists with reduced-dose fibrinolytic agents enhances clot lysis efficacy.
  • These combined approaches appear to achieve improved reperfusion without a significant increase in bleeding complications.

Conclusions:

  • Advancements in fibrinolytic and antithrombotic therapies offer significant potential for improving outcomes in acute coronary syndromes.
  • Single-bolus administration and the use of glycoprotein IIb/IIIa receptor antagonists represent promising strategies for more effective and timely reperfusion.
  • Future therapeutic paradigms may focus on these enhanced approaches for earlier and safer treatment of ST-segment elevation acute coronary syndromes.

Related Experiment Videos